GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oxford Biodynamics OBD.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

0.10p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Oxford Biodynamics

Its shares trade on LSE under the ticker OBD.L. It has been listed since 6 December 2016. In the fiscal year to 30 September 2025, it reported revenue of £1.1m and a net loss of £11.2m. At that date it held total assets of £8.1m and shareholders' equity of £1.1m.

Oxford BioDynamics Plc is a biotechnology company, which engages in the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The firm focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. Its geographical segments include UK and Malaysia. Its EpiSwitch is an industrial platform for the discovery, evaluation, validation and monitoring of a class of epigenetic biomarkers known as chromosome conformation signatures (CCSs). EpiSwitch is a biomarker technology platform that facilitates pharmaceutical and biotechnology companies in their therapeutic development programs and the development of companion diagnostics. The EpiSwitch technology has validated biomarkers in a range of diseases, including Alzheimer's disease, breast cancer, ulcerative colitis and liver cancer. Its service offering includes predictive biomarkers, prognostic biomarkers, residual disease monitoring biomarkers, diagnostic biomarkers and companion diagnostic biomarkers.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
6 Dec 2016
Employees
37

Leadership

Pay as last reported

  • Mr. Iain RossExecutive Chairman of the Board, since 2025
  • Mr. Paul StockdaleChief Financial Officer, Executive Director, since 2017£180,000
  • Dr. Alexandre AkoulitchevChief Scientific Officer, Executive Director, since 2007£204,000
  • Mr. Stephen DiggleNon-Executive Director
  • Mr. Peter PreslandNon-Executive Director
  • Dr. David HolbrookNon-Executive Independent Director£47,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Oxford Biodynamics PLC possesses several strengths that contribute to its competitive advantage in the market:

Weaknesses

  • Despite its strengths, Oxford Biodynamics PLC also faces certain weaknesses that may hinder its growth and performance:

Opportunities

  • Oxford Biodynamics PLC can leverage various opportunities to further enhance its position and drive growth:

Threats

  • Oxford Biodynamics PLC faces certain threats that could impact its growth and profitability:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.